The Pipeline for iPSC-Derived Cell Therapeutics in 2025 

Today, at least 74 cell therapy companies worldwide are developing iPSC-derived therapeutics for human use, an astounding level of growth for a cell type discovered less than 20 years ago. In addition, a growing number of research institutes, government agencies, and academic centers are contributing to the field. This article highlights the pioneering companies and organizations leading the way in advancing iPSC-derived cell therapies.

The Scalable Solution for 10X Exosome Yield

Biological components in conditioned media block filters and lead to significant particle loss during downstream processing of exosomes. AgentV™-DSP is a solution specifically designed to address filtration problems by preventing filter fouling and provide novel processing advantages such as greater filter loading capacity and greater exome yield. Each bottle of this powerful reagent treats 5L of media and can increase your particle yield
10-fold.

Take Your Biotherapies Expertise to the Next Level! Free CABP Exam Prep Bootcamps Series From AABB

Provided by the Association for the Advancement of Blood & Biotherapies (AABB), the CABP is a pioneering credentialing exam, identifying high-caliber professionals in cell and gene therapy. Becoming a CABP is a mark of distinction contributing to the advancement of the field by demonstrating a high standard of competence across key domains of knowledge. AABB has introduced an exam prep bootcamps series supporting candidates on their journey to earning this prestigious credential, with each expert-developed bootcamp covering one of the CABP exam domains.

Bonus offer: For complimentary access to the full bootcamp series usually worth $275, AABB encourages candidates to submit a CABP application (subject to approval). Learn more about the CABP, the bootcamp series and how to apply on the AABB website.

Incucyte® CX3 System transforms continuous analysis of 3D cell models with confocal imaging and unmatched throughput

Göttingen, Germany | August 1, 2025 – The life science group Sartorius launches the new Incucyte® CX3 Live-Cell Analysis System, delivering the most advanced capabilities for 3D cell culture applications. Expanding the Incucyte® instrument portfolio, the CX3 combines innovative confocal fluorescence imaging, flexible throughput, and powerful software to streamline workflows and accelerate decision-making across discovery and development.

TriHaz Solutions Opens New Nashville, Tennessee Facility to Expand Regulated Medical Waste Services Across Tennessee

Nashville, TN, July 16, 2025 – TriHaz Solutions, a trusted provider of regulated medical waste management, is proud to announce the opening of a new operational facility in Nashville, Tennesee. This expansion strengthens TriHaz’s ability to serve healthcare facilities, laboratories, and clinical operations throughout Tennessee with reliable and fully compliant medical waste disposal services.

Future Medical Products LLC Announces the Launch of PBME Topical™ (Pure Bone Marrow Exosomes)

July 24, 2025, St. Louis, Missouri — Future Medical Products LLC announces the launch of PBME Topical (“Pure Bone Marrow Exosomes”). PBME Topical is a cosmetic product in compliance with the Modernization of Cosmetics Regulation Act of 2022 (MoCRA). PBME Topical consists of isolated exosomes from mesenchymal stem cells, the most studied cell in science. These exosomes are composed of phospholipid bilayers with transmembrane proteins and receptors, integrated growth factors, in addition to micro-RNA and messenger-RNA. 

REPROCELL’s StemRNA™ iPSC Seed Stock Clones for Seamless Translational Research

The translation of stem cell therapies begins with a well-characterized and thoroughly documented starting cell source. REPROCELL’s StemRNA™ Clinical iPSC Seed Stock Clones offer cell therapy developers streamlined starting material that provides a gateway into early-stage clinical development. By combining regulatory alignment with ethical sourcing and footprint-free mRNA reprogramming, REPROCELL now offers various male and female, ready-to-use, clinical-grade iPSC lines manufactured in our facilities, in the U.S. and Japan.

Gameto Secures $44M Series C to Advance Fertilo as First iPSC-Derived Reproductive Therapy to Reach Phase 3 in the U.S.

AUSTIN, Texas, Aug. 12, 2025 - Gameto, a clinical-stage biotechnology company developing iPSC-derived therapies for reproductive health, has completed its $44 million Series C financing round. Fertilo is already cleared to commercialize many ex-U.S. jurisdictions and is currently used in clinics in Peru, Mexico and Australia, with additional clearances in Japan, India, Singapore, Guatemala, Argentina, Dominican Republic, and Paraguay. Five babies have been born with Fertilo so far and over 20 pregnancies have been recorded. Fertilo is also the first iPSC-derived therapy to reach late-stage clinical development in the United States.

Mirugen Secures A$4.5M to Advance In Vivo Cell (Re)programming, Positioning Itself as a Pioneer in the Field

Melbourne, Australia, August 14 2025 – Mirugen Pty Ltd, a preclinical biotechnology company (re)programming cells to unlock innate cellular repair mechanisms, announced the successful close of a seed financing round, and the appointment of Charlotte Casebourne Stock as Executive Chair. To date, Mirugen has raised A$7.1M. The proceeds from this financing round will support the development of Mirugen’s lead Retinitis Pigmentosa programme through translational development.

Japan Moves Toward Permitting Fertilized Embryo Research Using iPSC-Derived Eggs and Sperm

A Japanese government bioethics panel has given the green light to a controversial but closely regulated area of research: the creation of human embryos using lab-generated sperm and eggs derived from pluripotent stem cells, including induced pluripotent stem (iPS) cells. The panel’s recommendation allows this practice strictly for scientific research focused on infertility and genetic diseases—not for reproductive purposes.

Longeveron® Announces Licensing of New Cardiac Selective iPSC Technology for Cardiovascular Disease

MIAMI, July 21, 2025 —  Longeveron Inc. (NASDAQ: LGVN) announced that it has licensed an issued US patent (12,168,028 B2) for a stem cell technology from the University of Miami. The composition of matter patent protects unique induced pluripotent derived cardiomyogenic cells that have widespread therapeutic indications for heart diseases. The stem/precursor cells protected by this patent are obtained by deriving cells that bear a cell surface receptor known as the GHRH-Receptor. These cells are uniquely able to differentiate into human cardiac muscle cells and have the potential to be safer than existing strategies.

First-in-Human Trial of OpCT-001: An iPSC-Derived Cell Therapy for Primary Photoreceptor Diseases 

Berlin, Germany, and Cambridge, MA, USA July 8, 2025 – Bayer AG and BlueRock Therapeutics LP, a clinical-stage cell therapy company and wholly owned subsidiary of Bayer AG, \announced that the first patient received the investigational therapy in CLARICO, a Phase 1/2a clinical trial of OpCT-001, an investigational iPSC-derived cell therapy for the treatment of primary photoreceptor diseases. OpCT-001 is the first iPSC-derived investigational cell therapy to be clinically tested for treating primary photoreceptor (PR) diseases.

Novel iPSC-Based Vaccine Shows Promise Against Colorectal Cancer

Colorectal cancer (CRC) remains one of the leading causes of cancer-related deaths worldwide, claiming nearly a million lives each year. Despite advances in screening, surgery, and chemotherapy, the disease continues to pose a formidable clinical challenge, particularly when diagnosed at advanced stages. In recent years, researchers have increasingly turned to the immune system as a powerful ally in the fight against cancer. Now, a team at National Taiwan University has developed a novel vaccine strategy that may represent a major leap forward utilizing groundbreaking iPSC technology.

iPSC-Derived NK Cells and the Future of Immunotherapy

Natural Killer (NK) cell therapies are rapidly emerging as a transformative force in healthcare, with promising potential across a range of conditions. They feature the complex killing capacity of classic immune system T cells but lack the prolonged time required for them to respond. With the armoury to rapidly detect and remove damaged, infected, senescent and cancerous cells throughout the body, they are nature’s frontline cell-mediated attack force. This capability has sparked considerable interest in developing NK cell-based therapies for cancer treatment and other conditions. 

Venture Capital Funding Flowing into the iPSC Sector by Year

The induced pluripotent stem cell (iPSC) sector has attracted strong venture capital funding in recent years, reflecting growing confidence in its potential across regenerative medicine, drug development, toxicology testing, personalized medicine, and disease modeling. From 2021 to today, numerous companies secured substantial investments, signaling a promising future for iPSC-based innovations. This article examines key funding events in the sector, analyzing the scale of investments, their trajectory over time, and the companies driving industry growth.

The Remarkable Rise of iPSC-derived MSC Therapeutics: iMSCs

The rise of iPSC-derived mesenchymal stem cells (iMSCs) represents a significant evolution in regenerative medicine. iMSCs are generated by reprogramming adult somatic cells, typically fibroblasts, into induced pluripotent stem cells (iPSCs), which are then differentiated into mesenchymal stem cells (MSCs). This breakthrough technology offers several advantages over traditional MSC therapies, which are often derived from limited, patient-specific sources such as bone marrow or adipose tissue.

Pivotal Trends Impacting the Global Cord Blood and Tissue Industry in 2025

The cord blood industry emerged in the early 1990s with the establishment of banks in the U.S. and abroad, nearly 40 years after the discovery that stem and progenitor cells were present in human cord blood. Since then, the field has advanced into a global industry with applications in stem cell transplantation, regenerative medicine, and cellular therapy. Today, six pivotal themes are shaping the future of the cord blood and tissue sector, influencing its growth, innovation, and clinical impact worldwide.

[SALE] Global Database of Regenerative Medicine Industry Investors, 2025

Regenerative medicine companies are those involved with cell therapies, gene therapies, exosomes, tissue engineering, biomaterials, or other therapies involving the use of human cells and tissues. Understandably, investor capital is often needed to support these therapeutics from preclinical development through clinical trials to commercialization. This database reveals the identity and investment behavior of 300+ investors who specialize in companies commercializing regenerative medicine (RM) and advanced therapy (AT) products.

If you are in the process of raising investor capital, this database is a must-have. For 48 hours only, you can claim it for 50% off.

[SALE] Mesenchymal Stem Cells / Medicinal Signaling Cells (MSCs) – Advances & Applications, 2025

Today, 12 MSC-based products have received regulatory approvals. This includes 11 full approvals and a 12th conditional approval within China. The Republic of Korea has approved five products; Japan and the EU have approved two products; and India, Iran, and Australia have approved one each. Market competitors have also developed 17 biomaterial-based MSCs and MSC progenitor products, which are largely being used for orthopedic indications. Companies like Cynata are pioneering iPSC-derived MSC (iMSC) production technologies, supporting large-scale therapeutic development. In total, at least eight companies are now developing iMSCs. 

For 48 hours only, you can claim this global strategic report for 40% off. 

[REPORT] Global CAR-T Cell Therapy Market - Market Size, Forecasts, Trials & Trends, 2025

Since 2017, 13 CAR-T cell therapies have reached commercialization. Seven therapies have been approved by the U.S. FDA, after which approvals for them were issued in other healthcare markets as well. These therapies include Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, Carvykti, and Aucatzyl.  Beyond the U.S., four CAR-T therapies—Relma-cel, Fucaso, Yuanruida, and Zever-cel—have been approved by China’s NMPA. Additionally, two therapies, NexCAR19 and Qartemi, have received approval from India’s CDSCO. This report reveals market size figures for the Global CAR-T Cell Therapy Market, segmented by Product, Geography, and Indication, with forecasts through 2032.

[REPORT] Global Induced Pluripotent Stem Cell (iPSC) Industry Report – Market Size, Trends, & Forecasts, 2025

In addition to companies developing iPSC-derived cellular therapeutics, a growing number of competitors are commercializing iPSC products for diverse applications—ranging from drug discovery and disease modeling to toxicology testing, personalized medicine, tissue engineering, 3D bioprinting, and clean meat production. This report presents key industry metrics, including scientific publications, clinical trials, patents, funding rounds, strategic partnerships, and M&A activity. It identifies major global iPSC market players and provides detailed market size data segmented by Application, Technology, Cell Type, and Geography (North America, Europe, Asia-Pacific, and RoW), along with projections through 2030.

Interested to learn about other market segments, such as MSCs, iPSCs, CAR-T cells, exosomes, cord blood and tissue, or the cell therapy industry at large? 

Explore the BioInformant Shop.

*Want to advertise in this newsletter? Contact us at Info@BioInformant.com.